HEINER DREISMANN, PH.D. - Corporate Board Profile

MYRIAD GENETICS INC

Filing Date	Source Excerpt
2013-10-15	Heiner Dreismann, Ph.D. (2) (4) 60 Director ... Member of the Compensation Committee. ... Member of the Audit Committee. ... Member of the Strategic Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2013 to each of our non-employee directors who served during fiscal 2013. ... Heiner Dreismann, Ph.D. Fees Earned or Paid in Cash ($) 80,000 Option Awards ($) 304,854 Total ($) 384,854
2014-10-14	Heiner Dreismann, Ph.D. (2) (4) 61 Director ... (2) Member of the Compensation Committee. (4) Member of the Strategic Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2014 to each of our non-employee directors who served during fiscal 2014. Heiner Dreismann, Ph.D. Fees Earned or Paid in Cash ($) 80,000 Option Awards ($) 290,517 Total ($) 370,517
2015-10-15	Heiner Dreismann, Ph.D. (2) (4) 62 Director ... (2) Member of the Compensation Committee. (4) Member of the Strategic Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2015 to each of our nonemployee directors who served during fiscal 2015. ... Heiner Dreismann, Ph.D. 85,000 346,800 431,800
2016-10-11	Heiner Dreismann, Ph.D. (2)(4) 63 Director ... (2) Member of the Compensation Committee. (4) Member of the Strategic Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2016 to each of our nonemployee directors who served during fiscal 2016. Heiner Dreismann, Ph.D. 89,000 Fees Earned or Paid in Cash ($) 318,525 Restricted Stock Unit Awards ($) 407,525 Total ($)
2017-10-12	Heiner Dreismann, Ph.D., a director of Myriad since June 2010, ... Member of the Compensation Committee. ... Member of the Audit Committee. ... Member of the Strategic Committee. ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2017 to each of our nonemployee directors who served during fiscal year 2017. ... Heiner Dreismann, Ph.D. ... 85,000 Fees Earned or Paid in Cash, 250,000 Restricted Stock Unit Awards, 335,000 Total.
2018-10-10	Heiner Dreismann, Ph.D. (2) (4) 65 Director ... Member of the Compensation Committee. ... Member of the Audit Committee. ... Member of the Strategic Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2018 to each of our nonemployee directors ... Heiner Dreismann, Ph.D. 334,994
2019-10-16	Heiner Dreismann, Ph.D. (2) (4) 66 Director ... Member of the Compensation Committee. ... Member of the Audit Committee. ... Member of the Strategic Committee ... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2019 to each of our nonemployee directors ... Heiner Dreismann, Ph.D. 85,000 Fees Earned or Paid in Cash, 299,988 Restricted Stock Unit Awards, 384,988 Total.
2020-10-15	Heiner Dreismann, Ph.D., joined as a Director of Myriad in June 2010... The Compensation Committee currently has five members: Dr. Dreismann (chair)... The following table shows the total compensation paid or accrued during the fiscal year ended June 30, 2020 to each of our nonemployee directors... Heiner Dreismann, Ph.D. 84,375 300,005 384,380
2021-04-15	Heiner Dreismann, Ph.D., joined as a Director of Myriad in June 2010... Age: 67... Committees: Compensation and Human Capital Committee (Chair)... Director Compensation Table: Heiner Dreismann Fees Earned or Paid in Cash: 58,750, Stock Awards: 299,984, Total: 358,734.
2022-04-14	Heiner Dreismann, Ph.D., joined as a Director of Myriad in June 2010. He had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and member of Roche’s Global Diagnostic Executive Committee. During the past five years, Dr. Dreismann served on the Board of Directors of Med BioGene, Inc., Genenews Limited, Interpace Diagnostics and Ignyta, Inc. He earned a M.S. degree in biology and his Ph.D. in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany. The Board of Directors has determined that Dr. Dreismann should serve on the Board for the following reasons: He provides the Board with important business and managerial expertise from his more than 20 years at Roche, including specific expertise in developing and commercially launching diagnostic products. Furthermore, Dr. Dreismann has extensive experience in international markets, specifically in Europe, while he was CEO of Roche Molecular Systems, the international leader in molecular diagnostics, which is important as we seek to expand internationally. His scientific background and expertise also enable him to provide the Board with technical advice on product research and development. Dr. Dreismann has a diversified background in managing and serving as a director of several companies in the healthcare industry. Age:68 Director Since:2010 Committees: Compensation and Human Capital Committee, Research and Product Innovation Committee
2023-04-12	Heiner Dreismann, Ph.D., joined as a director of Myriad in June 2010. He had a successful career at the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development for Roche Diagnostics and member of Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves as the Chairman of the board of Mainz Biomed N.V. Previously, Dr. Dreismann served on the board of directors of Med BioGene, Inc., Genenews Limited, Interpace Diagnostics and Ignyta, Inc. He also currently serves on a number of early-stage private company boards in the biotechnology industry. He earned a M.S. degree in biology and his Ph.D. in microbiology/molecular biology (summa cum laude) from Westfaelische Wilhelms University (The University of Münster) in Germany. The Board has determined that Dr. Dreismann should serve on the Board for the following reasons: He provides the Board with important business and managerial expertise from his more than 20 years at Roche, including specific expertise in developing and commercially launching diagnostic products. Furthermore, Dr. Dreismann has extensive experience in international markets, specifically in Europe, while he was CEO of Roche Molecular Systems, the international leader in molecular diagnostics, which is important as we seek to expand internationally. His scientific background and expertise also enable him to provide the Board with technical advice on product research and development. Dr. Dreismann has a diversified background in managing and serving as a director of several companies in the healthcare industry.
2024-04-17	Heiner Dreismann, Ph.D., joined as a director of Myriad in June 2010... The following table shows the total compensation paid or accrued during the year ended December 31, 2023 to each of our non-employee directors who served during fiscal year 2023... Heiner Dreismann, Ph.D. $93,500 cash fees and $349,988 stock awards totaling $443,488.